Recent Press Releases

Merck Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma

- First patient begins treatment in an international Phase II study investigating the efficacy and safety of MSB0010718C in patients with metastatic Merkel...

GSK's TanzeumTM is now available in pharmacies in the U.S.

GSK (LSE/NYSE: GSK) today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in...

Accelerator Corporation Secures $51.1 Million to Support Emerging Biotechnology Research Opportunities in New York City and Seattle

Accelerator IV to Bridge Funding Gap for Early Research;Includes New Strategic Investors Eli Lilly and Company, Harris & Harris Group, Inc., Johnson & Johnson Development Corporation, The...

BIOPHARMA INDUSTRY LEADER AMY SCHULMAN JOINS POLARIS PARTNERS

BOSTON , MASS., Jul 29, 2014 (GLOBE NEWSWIRE via COMTEX) -- Polaris Partners today announced the hiring of biopharmaceutical executive Amy Schulman as a Venture Partner, based out of Boston....

KaloBios Provides Update on KB001-A Partnership and Clinical Status

SOUTH SAN FRANCISCO, Calif. -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today provided an update on the status of the KB001-A development program, including an update on its KB001-A...

IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p

HORSHAM, Pa., July 28, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) capsules for the...

Biodel Enters Into $15 Million Equity Commitment With Lincoln Park Capital

DANBURY, CT, Jul 28, 2014 (Marketwired via COMTEX) -- Biodel Inc. BIOD -3.65% today announced that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC...

Retrophin Proposes Acquisition of Clinuvel Pharmaceuticals

July 27, 2014 11:47 PM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced that on July 17, 2014 it submitted a proposal to the Board of Directors of...

AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291

AstraZeneca today announced it has entered into collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca's investigational compound in clinical...

Specialty Vaccine Company PaxVax Secures Up to $60 Million in Financing

Specialty Vaccine Company PaxVax Secures Up to $60 Million in Financing Proceeds to Support New European Operations and Clinical Development, Regulatory Review and Anticipated Global Launch of...

Zealand and Boehringer Ingelheim sign second collaboration agreement to advance novel peptide medicines

Jul 28, 2014 (GLOBE NEWSWIRE via COMTEX) -- Company Announcement No. 11/2014 Zealand eligible to receive up to EUR 295 million in potential milestone payments for the first commercialized product...

AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso™

AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso™ REDWOOD CITY, Calif., July 25, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (...

Global Computational Biology Market By Application (Cellular & Biological Simulation, Pharmacogenomics, Drug Discovery), By Services (In-house, Contract), By End User (Academics, Industry, Commercial) Expected To Reach USD 4,285.1 Million By 2020

The global market for computational biology is expected to reach USD 4,285.1 million by 2020 growing at a CAGR of 21.1%, according to a new study by Grand View Research, Inc. Steady increase in the...

Amgen Announces 2014 Third Quarter Dividend

THOUSAND OAKS, Calif., July 25, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directo

European CHMP Adopts Positive Opinion for Gilead's Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma

FOSTER CITY, Calif.--Jul. 25, 2014-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European...

Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the American Society of Nephrology

NEW YORK -- Keryx Biopharmaceuticals, Inc. (KERX) (the "Company") announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric...

Ultragenyx Pharmaceuticals (RARE) Appoints Sunil Agarwal, M.D. As Chief Medical Officer And Senior Vice President

NOVATO, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...

Innocoll AG Announces Pricing of Initial Public Offering

ATHLONE, Ireland, July 25, 2014 -- Innocoll AG (the "Company"), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical...